Carson Wealth (CWM LLC)
IKT icon

Carson Wealth (CWM LLC)’s Inhibikase Therapeutics IKT Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.6K Buy
16,419
+16,346
+22,392% +$29K ﹤0.01% 4225
2025
Q4 		$0 Buy
73
+54
+284% +$86 ﹤0.01% 5490
2025
Q3 		$0 Buy
+19
New +$33 ﹤0.01% 5398

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Carson Wealth (CWM LLC)'s IKT Position: Q1 2026 in Review

Carson Wealth (CWM LLC) increased its Inhibikase Therapeutics (IKT) stake by 22,392% in Q1 2026, buying an estimated $29K and bringing the position to 16,419 shares worth $27.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4225.

Carson Wealth (CWM LLC) first reported a position in IKT in Q3 2025 and has held it in 3 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Carson Wealth (CWM LLC) held 16,419 shares of Inhibikase Therapeutics worth $27.6K as of Q1 2026.
  • Carson Wealth (CWM LLC) bought 16,346 Inhibikase Therapeutics shares in Q1 2026, an estimated $29K.
  • Inhibikase Therapeutics made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #4225 holding.
  • Carson Wealth (CWM LLC) first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.